Reducing R&D Cycle Time in Pharma Without Increasing Regulatory Risk - with Vaithi Bharath of Bayer (38 min)
- Release date: 2026-01-07
- Listen on Spotify: Open episode
- Episode description:
Today's guest is Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer. Bharath joins Emerj Editorial Director Matthew DeMello to break down why clinical R&D timelines often slip for reasons that have little to do with model performance. Rather, delays compound when data moves across fragmented systems, teams rely on slow handoffs, and validation requirements turn minor adjustments into major cycle-time hits. He walks through where decision-making slows from data capture through database lock, and what it takes to accelerate workflows without replacing a validated environment. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! This episode is sponsored by AnswerRocket.
Summary
- 🚧 Systemic Delays Dominate: Pharma R&D bottlenecks stem from fragmented systems, manual handoffs, and rework across EDC, CTMS, and stats—not analytics models themselves.
- ⚖️ Validation Gates Amplify Issues: Regulations like 21 CFR Part 11 demand exhaustive CSV/GxP for changes, turning tweaks into weeks via audits, e-signs, and reproducibility proofs.
- 🤖 AI as Compliant Copilot: Guided, explainable workflows handle routine QC/protocol checks with human-in-loop reviews, ensuring audit-ready lineage without replacing stacks.
- 🔗 Layer, Don’t Replace: API wrappers and adapters enable quick wins on Veeva/Medidata, avoiding revalidation while adding traceability and speed.
- 📈 Path to Faster Cycles: Standardize top rework questions, pilot in sandboxes, track savings, and scale—yielding reusable macros, shorter locks, and consistent quality.
Insights
What fragmented handoffs turn hours of clinical insights into weeks of waiting in pharma R&D?
Time: 3:35 – 8:07
Category: AI for Personalized MedicineAnswer: Clinical data flows through disparate systems like EDC (Medidata/Veeva), CTMS, labs, safety databases, and stats environments, requiring manual transformations to SDTM/ADaM datasets, reconciliations, and protocol checks. This leads to database lock delays from days to weeks due to rework across teams and vendors. (Start at 3:35)
Why does a minor data tweak unleash a validation nightmare in regulated environments?
Time: 8:20 – 11:05
Category: AI Governance & LawsAnswer: Small changes like ETL pipeline updates or format incompatibilities trigger GxP/CSV processes with extensive documentation, testing, and assertions on what must/must not happen. Real-world example: 6-8 months of manual zip file handoffs with lineage checks due to poor integration performance. (Start at 8:20)
What tamper-proof trails do auditors demand to trust your pharma data integrity?
Time: 11:45 – 15:32
Category: AI Governance & LawsAnswer: 21 CFR Part 11 mandates robust audit trails, secure access, e-signatures, and reproducibility so regulators can rerun code/data to match results. Global trials add stringency from EMA/China, amplifying needs beyond non-regulated spaces. (Start at 11:45)
Which routine checks should AI guide first to accelerate database locks?
Time: 15:55 – 20:35
Category: AI for Personalized Medicine, AI Governance & LawsAnswer: AI-guided workflows for dataset readiness, protocol deviations, QC flags, and safety signals provide suggestions with immutable audit trails, but humans review for compliance with study plans. This cuts mundane efforts while maintaining domain expertise. (Start at 15:55)
Can standardized AI macros boost reusability and consistency across clinical studies?
Time: 20:35 – 26:40
Category: AI for Personalized MedicineAnswer: Guided processes enable 70-80% reusable macros for validations, reducing study-specific tweaks, review times, SAP amendments (costing $100k+), and enabling faster locks with uniform quality/audit trails regardless of team experience. (Start at 20:35)
How can API wrappers supercharge legacy pharma stacks without revalidation chaos?
Time: 26:47 – 32:01
Category: AI-Driven Innovation EconomyAnswer: Build adapters on existing systems like Veeva APIs for lineage tracking and QC checks, layering AI workflows that plug into ETL/validation without altering cores. This avoids months/years of rip-and-replace, enabling quick pilots in parallel. (Start at 26:47)
Is a data lakehouse the key to unshackling analysts from wrangling drudgery?
Time: 32:12 – 35:09
Category: AI-Driven Innovation EconomyAnswer: Consolidate disparate feeds (EDC/labs/safety) into a central lakehouse for upstream prep, allowing stats teams to focus on insights over integrations. This shifts burden, cuts decision cycles, and leverages API-plug standards like Databricks. (Start at 32:12)